Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S. Tam, Andrew W. Roberts, Mary Ann Anderson et al.|New England Journal of Medicine|2018Cited by 429
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Andrew W. Roberts, Jing Deng et al.|Blood|2016Cited by 329
T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironmentsEdwin D. Hawkins, Cristina Lo Celso, Katie Foster et al.|Nature|2016Cited by 205
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaChan Y. Cheah, John F. Seymour, Kirsten Herbert et al.|British Journal of Cancer|2014Cited by 132
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in <i>NPM1</i> mutated or <i>KMT2A-</i>rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform TrialSun Loo, Andrew H. Wei, Harry Iland et al.|Blood|2024Cited by 9